Actively Recruiting

Phase Not Applicable
Age: 5Years - 15Years
All Genders
Healthy Volunteers
NCT05318365

Bladder and Bowel Dysfunction in Children

Led by University of Aarhus · Updated on 2024-05-08

100

Participants Needed

3

Research Sites

169 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Background: Bladder and bowel dysfunction (BBD) is characterized by lower urinary tract symptoms accompanied by bowel complaints. BBD is a common condition in childhood. The present treatment strategy for BBD is a step-wise approach starting with management of bowel symptoms before initiation of standard urotherapy and further medical treatment of LUTS symptoms. This is, however, based on clinical experience and few retrospective, non-randomized studies and high-level evidence of the succession of the elements in treatment of BBD children is missing. Our microbiome, and its role in health and disease, has gained increased focus during the past years. Studies suggest the urine and gut microbiome to be critical for maintenance of a well-functioning bladder- and bowel system. The microbiome in children is only sparsely investigated and its role in BBD is to the investigator's knowledge still unexplored. Study 1: Aim: To investigate if combination therapy is more effective in treating urinary incontinence in BBD children. Materials and methods: A prospective randomized multicentre study on children with BBD (n=100) between 5-14 years and 9 months old. They are randomized to: 1) Medical treatment of bowel symptoms (n=50) or 2) Medical treatment of bowel symptoms combined with standard urotherapy. The effect of treatment will be evaluated after 3 months. Primary endpoint: Resolution of incontinence after treatment. Secondary endpoint: Improved quality of life after successful treatment of urinary incontinence. Study 2: Aim: To investigate the urofecal microbiome in children with BBD Materials and methods: 1. A cohort study to investigate, whether the urofecal microbiome can predict response to treatment and whether it changes during treatment period 2. A case control study to investigate whether the urofecal microbiome is different in children with BBD and recurrent UTI 's and children with BBD without recurrent UTI 's. The study population consists of children with BBD included in study 1. A urine-, stool sample and a perineum swab will be collected from all participants before and after treatment. Bacterial DNA will be extracted and the microbiome will be determined. Perspectives: BBD is a common condition in childhood. It is associated with a considerable psychological burden and a risk of more severe physical complications. The studies will provide basic knowledge about characteristics of the BBD patients and contribute new information about the optimal treatment of BBD children.

CONDITIONS

Official Title

Bladder and Bowel Dysfunction in Children

Who Can Participate

Age: 5Years - 15Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 5 to 14 years and 9 months at time of inclusion
  • Diagnosed with urinary incontinence and/or enuresis nocturna defined by ICCS criteria
  • Diagnosed with constipation and/or faecal incontinence defined by ROME IV criteria
  • Normal clinical examination
  • Parents or guardians can understand written and spoken information
  • Informed assent to participation from both parents or guardians
Not Eligible

You will not qualify if you...

  • Neuropathic or anatomical abnormalities in urinary tract or gastrointestinal canal
  • Previous urinary tract surgery (except circumcision)
  • Neurological illness or previous brain surgery
  • Ongoing urinary tract infection
  • Ongoing treatment with anticholinergics or β2-adrenoceptor agonists
  • Ongoing treatment with laxatives at correct dosage (PEG3350 1-2 g/kg/day)
  • Inflammatory bowel disease
  • Other disorders affecting bladder or bowel function
  • Use of systemic antibiotics within past 3 months (for microbiome study)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

Aalborg University Hospital

Aalborg, Denmark, 9000

Not Yet Recruiting

2

Aarhus University Hospital

Aarhus, Denmark, 8000

Actively Recruiting

3

Goedstrup Regional Hospital

Herning, Denmark, 7400

Actively Recruiting

Loading map...

Research Team

S

Sofie Axelgaard, MD

CONTACT

L

Luise Borch, MD, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here